BIONET Corp. (TPEX:1784)

Market Cap	3.80B
Revenue (ttm)	1.22B
Net Income (ttm)	76.54M
Shares Out	50.61M
EPS (ttm)	1.51
PE Ratio	49.73
Forward PE	n/a
Dividend	1.41 (1.86%)
Ex-Dividend Date	Oct 3, 2025

Volume	2,000
Average Volume	443,244
Open	75.80
Previous Close	75.10
Day's Range	75.10 - 76.50
52-Week Range	62.40 - 116.25
Beta	0.43
RSI	58.97
Earnings Date	Aug 11, 2025

About Everi Holdings

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.